References
- Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001;35:134–46.
- Makino I, Shinozaki K, Yoshino K, Nakagawa S. Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid. Nihon Shokakibyo Gakkai Zasshi. 1975;72:690–702.
- Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987;1:834–6.
- Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun. 1999;263:537–42.
- Qi HP, Wei SQ, Gao XC, Yu NN, Hu WZ, Bi S, Cui H. Ursodeoxycholic acid prevents selenite-induced oxidative stress and alleviates cataract formation: in vitro and in vivo studies. Mol Vis. 2012;18:151–60.
- Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut.1996;39: 475–8.
- Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol. 2002;64: 1661–7.
- Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ. 1999;6:842–54.
- Rodrigues CM, Stieers CL, Keene CD, Ma X, Kren BT, Low WC, Steer CJ. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem. 2000;75:2368–79.
- Qiao L, Yacoub A, Studer E, Gupta S, Pei XY, Grant S, et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology. 2002;35:779–89.
- Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991;324:1548–54.
- Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990;11:12–5.
- Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol. 1991;86:1194–9.
- Nishigaki Y, Ohnishi H, Moriwaki H, Muto Y. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig Dis Sci. 1996;41:1487–93.
- Yamazaki K, Suzuki K, Nakamura A, Sato S, Lindor KD, Batts KP, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology. 1999;30:71–8.
- Vaz A, Cunha C, Gomes C, Schmucki N, Barbosa M, Brites D. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Molecular Neurobiology. 2014:1–14.
- Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc Natl Acad Sci U S A. 2002;99:10671–6.
- Sola S, Castro R, Laires P, Steer C, Rodrigues C. Tauroursodeoxycholic acid prevents amyloid B peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003;9:226–34.
- Rodrigues CM, Spellman SR, Solá S, Grande AW, Linehan-Stieers C, Low WC, Steer CJ. Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab. 2002;22:463–71.
- Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJ.Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A. 2003;100:6087–92.
- Colak A, Kelten B, Sağmanligil A, Akdemir O, Karaoğlan A, Sahan E, et al. Tauroursodeoxycholic acid and secondary damage after spinal cord injury in rats. J Clin Neurosci. 2008;15:665–71.
- Park IH, Kim MK, Kim SU. Ursodeoxycholic acid prevents apoptosis of mouse sensory neurons induced by cisplatin by reducing P53 accumulation. Biochem Biophys Res Commun. 2008;377:1025–30.
- Parry GJ, Rodrigues CM, Aranha MM, Hilbert SJ, Davey C, Kelkar P, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. 2010;33:17–21.
- Min JH, Hong YH, Sung JJ, Kim SM, Lee JB, Lee KW. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci. 2012;27:200–6.
- Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713–7.
- Thao T, Ryu H, Yoo S, Rhee D. Antibacterial and anti-atrophic effects of a highly soluble, acid stable, UDCA formula in Helicobacter pylori-induced gastritis.Biochemical Pharm. 2008;75:2135–46.
- Berry JD, Shefner JM, Conwit R, Scboenfeld D, Keroack M, Felsenstein D, et al.Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 2013;8:e61177.
- Regression - hockey sticks, broken sticks, piecewise, change points. http://people.stat.sfu.ca/∼cschwarz/Stat-650/Notes/PDFbigbook-JMP/JMP-part019.pdf
- STAGE 3 Clinical Trial of Ceftriaxone in Subjects with ALS (S36.001). http://www.neurology.org/cgi/content/meeting_abstract/80/1_MeetingAbstracts/S36.001
- Ursodiol treatment report. http://www.patientslikeme.com/treatments/show/2016#overview
- ALS Therapy Development Institute. http://www.als.net/forum/yaf_postst47542p5_Ursodiol.aspx
- Ursodiol. http://www.goodrx.com/ursodiol/price#/?distance=6&filter-location=&coords=&label=ursodiol&form=tablet&strength=500mg&quantity=60.0&qty- custom=&language=&store-chain=.
- URSO 250®/URSO Forte®: (ursodiol tablets, USP) 250 mg & 500 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020675s013lbl.pdf.